Circio logoCircio logo

  • About
      • About Circio
      • CEO Statement
      • Pipeline
      • Management Team
      • Board of Directors
      • Careers
      • The Norwegian Transparency Act
  • circRNA
      • Circio AB
      • circVec platform
  • Clinical programs
      • KRAS program
      • Publications
  • Partnering
  • Investors
      • Press releases
      • Events
      • Financial calendar
      • Reports
      • Presentations
      • Prospectus
      • Share facts
      • Largest shareholders
      • Dividend policy
      • Analyst coverage
      • Registrar and auditor
      • Corporate Governance Policy
      • Code of Conduct
      • Corporate Social Responsibility Principles
      • Remuneration Principles
      • About General Meeting
        • General Meetings
      • Articles of Association
      • Board of Directors
        • Nomination Committee
        • Committees
      • Management
      • Contact
  • Media
      • Press releases
      • Events
      • Subscribe
      • Contact
  • Contacts
    • About
      • About Circio
      • CEO Statement
      • Our pipeline
      • Management Team
      • Board of Directors
      • Careers
      • The Norwegian Transparency Act
    • circRNA
      • Circio AB
      • circVec platform
    • Clinical programs
      • KRAS program
      • Publications
    • Partnering
      • Partnering
    • Investors
      • Warrants exercise 2024
      • Press releases
      • Events
      • Financial calendar
      • Reports
      • Presentations
      • Prospectus
      • Share information
        • Share and trading information
        • Largest shareholders
        • Dividend policy
        • Analyst coverage
        • Registrar and auditor
      • Corporate Governance Policy
      • Code of Conduct
      • Corporate Social Responsibility Principles
      • Remuneration Principles
      • About General Meeting
      • General Meetings
      • Articles of Association
      • Board of Directors
      • Nomination Committee
      • Committees
      • Management
      • Contact
    • Media
      • Press releases
      • Events
      • Subscribe
      • Contact
    • Contacts
      • Offices
      • Investors & Media

    Corporate news

    All press releases
    • Press releases - Regulatory
    • Press releases - Non-regulatory
    • All press releases
    2020
    • 2025
    • 2024
    • 2023
    • 2022
    • 2021
    • 2019
    • 2018
    • 2017
    • 2016
    Corporate news
    • All subjects
    • Other
    August 20, 2020
    Press release - Regulatory

    Targovax ASA: second quarter and first half 2020 results

    May 7, 2020
    Press release - Regulatory

    Targovax ASA: First quarter 2020 results

    March 20, 2020
    Press release - Non-regulatory

    Impact of corona virus (COVID-19) on Targovax’s operations

    March 11, 2020
    Press release - Regulatory

    Targovax ASA: Fourth quarter 2019 results

    March 11, 2020
    Press release - Regulatory

    Targovax ASA: Annual Report 2019

    March 3, 2020
    Press release - Non-regulatory

    Targovax announces completed enrollment in the ONCOS-102 trial in anti-PD1 refractory melanoma

    March 3, 2020
    Press release - Non-regulatory

    Targovax ASA: Invitation to presentation of Targovax’s fourth quarter 2019 results, Wednesday 11 March

    January 22, 2020
    Press release - Regulatory

    TARGOVAX ASA – SUCCESSFULLY COMPLETED PRIVATE PLACEMENT

    IR contact
    Dr Erik Digman Wiklund
    Dr Erik Digman Wiklund
    CEO
    erik.wiklund@circio.com
    (+47) 41 33 35 36
    Dr Lubor Gaal
    Dr Lubor Gaal
    CFO & Head of BD
    lubor.gaal@circio.com
    (+34) 683 343 811
    Circio logo

    Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines.

    • About
    • circRNA
    • Clinical programs
    • Partnering
    • Investors
    • Media
    • Contacts

    CONTACT

    Circio Holding ASA
    Email: contact@circio.com

    • Cookies
    • Privacy policy
    • STAY CONNECTED